DK3080274T3 - Fremgangsmåder og sammensætninger til genom-manipulation - Google Patents

Fremgangsmåder og sammensætninger til genom-manipulation Download PDF

Info

Publication number
DK3080274T3
DK3080274T3 DK14869719.6T DK14869719T DK3080274T3 DK 3080274 T3 DK3080274 T3 DK 3080274T3 DK 14869719 T DK14869719 T DK 14869719T DK 3080274 T3 DK3080274 T3 DK 3080274T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
genome manipulation
genome
manipulation
Prior art date
Application number
DK14869719.6T
Other languages
English (en)
Inventor
Jeffrey C Miller
David Paschon
Edward J Rebar
Thomas Wechsler
Lei Zhang
Original Assignee
Sangamo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Therapeutics Inc filed Critical Sangamo Therapeutics Inc
Application granted granted Critical
Publication of DK3080274T3 publication Critical patent/DK3080274T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DK14869719.6T 2013-12-09 2014-12-09 Fremgangsmåder og sammensætninger til genom-manipulation DK3080274T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913838P 2013-12-09 2013-12-09
US201461943884P 2014-02-24 2014-02-24
PCT/US2014/069352 WO2015089077A2 (en) 2013-12-09 2014-12-09 Methods and compositions for genome engineering

Publications (1)

Publication Number Publication Date
DK3080274T3 true DK3080274T3 (da) 2020-08-31

Family

ID=53270543

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14869719.6T DK3080274T3 (da) 2013-12-09 2014-12-09 Fremgangsmåder og sammensætninger til genom-manipulation

Country Status (12)

Country Link
US (6) US10081661B2 (da)
EP (3) EP3757116A1 (da)
JP (3) JP6535684B2 (da)
CN (3) CN105940013B (da)
AU (3) AU2014363991B2 (da)
CA (3) CA2931637C (da)
DK (1) DK3080274T3 (da)
ES (1) ES2813367T3 (da)
HK (1) HK1225754A1 (da)
HU (1) HUE051628T2 (da)
IL (3) IL245778B (da)
WO (2) WO2015089046A1 (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
EP3363903B1 (en) 2013-11-07 2024-01-03 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
ES2813367T3 (es) 2013-12-09 2021-03-23 Sangamo Therapeutics Inc Métodos y composiciones para ingeniería genómica
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
JP6606088B2 (ja) 2014-02-24 2019-11-13 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
DK3186376T3 (da) 2014-08-27 2019-05-06 Caribou Biosciences Inc Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
AU2016291778B2 (en) 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
JP6909212B2 (ja) * 2015-10-28 2021-07-28 サンガモ セラピューティクス， インコーポレイテッド 肝臓特異的コンストラクト、第ｖｉｉｉ因子発現カセット、およびその使用の方法
AU2016361350B2 (en) 2015-11-23 2023-04-06 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
KR20180088911A (ko) 2015-12-18 2018-08-07 상가모 테라퓨틱스, 인코포레이티드 Mhc 세포 수용체의 표적화된 붕괴
JP7128741B2 (ja) 2015-12-18 2022-08-31 サンガモ セラピューティクス， インコーポレイテッド Ｔ細胞受容体の標的化破壊
ES2895430T3 (es) * 2016-01-15 2022-02-21 Univ Minnesota Métodos y composiciones para el tratamiento de enfermedad neurológica
US10724020B2 (en) 2016-02-02 2020-07-28 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
CN106397599B (zh) * 2016-02-23 2020-08-07 上海交通大学 二价双特异性抗体杂交蛋白的表达和制备方法
US11471462B2 (en) 2016-06-27 2022-10-18 The Broad Institute, Inc. Compositions and methods for detecting and treating diabetes
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
BR112019003327A2 (pt) 2016-08-24 2019-07-02 Sangamo Therapeutics Inc nucleases manipuladas de alvo específico
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
BR112019003100A2 (pt) 2016-08-24 2019-07-09 Sangamo Therapeutics Inc regulação da expressão gênica usando nucleases manipuladas
CA3035534A1 (en) * 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
AU2017374042B2 (en) * 2016-12-09 2024-02-15 Acuitas Therapeutics, Inc. Delivery of target specific nucleases
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018126087A1 (en) * 2016-12-29 2018-07-05 Applied Stemcell, Inc. Gene editing method using virus
US20230190958A1 (en) * 2017-01-13 2023-06-22 Jichi Medical University AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2020518245A (ja) 2017-05-03 2020-06-25 サンガモ セラピューティクス， インコーポレイテッド 嚢胞性線維症膜貫通コンダクタンス制御因子（ｃｆｔｒ）遺伝子の改変のための方法および組成物
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP7123982B2 (ja) 2017-06-15 2022-08-23 ツールゲン インコーポレイテッド 肝臓において目的のタンパク質を発現するためのプラットフォーム
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
EP3676376A2 (en) 2017-08-30 2020-07-08 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
US20220080055A9 (en) * 2017-10-17 2022-03-17 Crispr Therapeutics Ag Compositions and methods for gene editing for hemophilia a
WO2019089913A1 (en) * 2017-11-01 2019-05-09 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
MA51637A (fr) * 2018-01-12 2020-11-18 Bayer Healthcare Llc Compositions et méthodes pour l'édition génique par ciblage de la transferrine
US11401512B2 (en) * 2018-02-08 2022-08-02 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2019161310A1 (en) * 2018-02-16 2019-08-22 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing by targeting fibrinogen-alpha
EP3772928A4 (en) 2018-04-06 2021-12-29 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
CN108795986A (zh) * 2018-05-31 2018-11-13 深圳市免疫基因治疗研究院 一种a型血友病慢病毒载体、慢病毒及其制备方法和应用
CN112805375A (zh) * 2018-08-07 2021-05-14 桑格摩生物治疗股份有限公司 用于治疗ii型黏多糖贮积症的方法
CN112867792A (zh) 2018-08-23 2021-05-28 桑格摩生物治疗股份有限公司 工程化靶特异性碱基编辑器
KR20210049133A (ko) * 2018-08-24 2021-05-04 씨에스엘 베링 진 테라피, 인크. 무혈청 배지에서 벡터 제조
AU2019344927A1 (en) 2018-09-18 2021-04-01 Sangamo Therapeutics, Inc. Programmed cell death 1 (PD1) specific nucleases
CA3116331A1 (en) * 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix
SG11202103733SA (en) * 2018-10-18 2021-05-28 Intellia Therapeutics Inc Compositions and methods for transgene expression from an albumin locus
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020162978A1 (en) * 2019-02-06 2020-08-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
AU2020221340A1 (en) 2019-02-15 2021-09-16 Bayer Healthcare Llc Gene editing for hemophilia A with improved Factor VIII expression
WO2020191249A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
MA55531A (fr) 2019-04-02 2022-02-09 Sangamo Therapeutics Inc Procédés pour le traitement de béta-thalassémie
WO2020206162A1 (en) * 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
US11702644B2 (en) * 2019-04-11 2023-07-18 California Institute Of Technology Methods and compositions for in vivo gene editing based cell-type-specific cellular engineering
EP3973067A1 (en) * 2019-05-21 2022-03-30 Sangamo Therapeutics, Inc. Controlled transgene expression in regulatory t cells
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
WO2021028359A1 (en) 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
WO2021083073A1 (zh) * 2019-10-31 2021-05-06 华东师范大学 一种基于肝细胞Alb基因的疾病治疗的产品
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
US20220064596A1 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
WO2022226218A1 (en) * 2021-04-21 2022-10-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Hsv amplicon packaging system using engineered cells
CA3232470A1 (en) * 2021-10-27 2023-05-04 Leah SABIN Compositions and methods for expressing factor ix for hemophilia b therapy
WO2023220043A1 (en) 2022-05-09 2023-11-16 Synteny Therapeutics, Inc. Erythroparvovirus with a modified genome for gene therapy
WO2023220040A1 (en) 2022-05-09 2023-11-16 Synteny Therapeutics, Inc. Erythroparvovirus with a modified capsid for gene therapy
WO2023220035A1 (en) 2022-05-09 2023-11-16 Synteny Therapeutics, Inc. Erythroparvovirus compositions and methods for gene therapy

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP0770129B1 (en) 1994-01-18 2005-11-23 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
ATE410518T1 (de) 1994-03-23 2008-10-15 Univ Ohio Kompaktnukleinsäure und ihre verabreichung in zellen
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
USRE45795E1 (en) 1994-08-20 2015-11-10 Gendaq, Ltd. Binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
AU5588298A (en) 1996-12-02 1998-06-29 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
CA2312291A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
EP1060261B1 (en) 1998-03-02 2010-05-05 Massachusetts Institute of Technology Poly zinc finger proteins with improved linkers
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
DE60023936T2 (de) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
KR20020086508A (ko) 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 약물 발견용 세포
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
ATE420189T1 (de) 2000-04-28 2009-01-15 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20050267061A1 (en) 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2002336373A1 (en) 2001-08-20 2003-03-03 The Scripps Research Institute Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US8106255B2 (en) 2002-01-23 2012-01-31 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7238346B2 (en) 2002-07-08 2007-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw High capacity recombinant adenoviral vector for treatment of hemophilia A
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
CA2497913C (en) 2002-09-05 2014-06-03 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005233550B2 (en) 2004-04-08 2010-11-18 Sangamo Therapeutics, Inc. Treatment of neuropathic pain with zinc finger proteins
US20080131962A1 (en) 2006-05-25 2008-06-05 Sangamo Biosciences, Inc. Engineered cleavage half-domains
AU2005287278B2 (en) 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
MX2007013757A (es) 2005-05-05 2008-01-24 Univ Arizona Reagrupacion permitida de secuencia (seer)-met odo de novedad para visualizar secuencias de adn especificas.
EP1913149A4 (en) 2005-07-26 2009-08-05 Sangamo Biosciences Inc TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
DK2484758T3 (da) 2005-10-18 2014-01-06 Prec Biosciences Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet
US8129510B2 (en) 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
WO2007139982A2 (en) 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
WO2008109467A1 (en) 2007-03-02 2008-09-12 Arizona Board Of Regents For And On Behalf Of Arizona State University Electrically conducting porphyrin and porphyrin-fullerene electropolymers
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
CN107501370B (zh) 2007-06-19 2021-06-18 路易斯安那州州立大学及农业机械学院管理委员会 信使rna帽的抗-反向硫代磷酸类似物的合成和用途
US8790345B2 (en) 2007-08-21 2014-07-29 Zimmer, Inc. Titanium alloy with oxidized zirconium for a prosthetic implant
JP5763341B2 (ja) 2007-09-27 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 生物学的活性のあるヌクレアーゼの迅速なインビボ同定法
WO2009054985A1 (en) 2007-10-25 2009-04-30 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
WO2009130208A1 (en) 2008-04-22 2009-10-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
CA2734235C (en) 2008-08-22 2019-03-26 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
AU2009322964B2 (en) 2008-12-04 2014-10-09 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
CA2756833C (en) 2009-04-09 2019-11-19 Sangamo Biosciences, Inc. Targeted integration into stem cells
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2011012316A2 (de) 2009-07-31 2011-02-03 Ludwig-Maximilians-Universität Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
ES2751916T3 (es) 2010-02-08 2020-04-02 Sangamo Therapeutics Inc Semidominios de escisión genomanipulados
JP2013518602A (ja) 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ， インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
JP5952263B2 (ja) 2010-04-26 2016-07-13 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガーヌクレアーゼを使ったｒｏｓａ遺伝子座のゲノム編集
US9175280B2 (en) * 2010-10-12 2015-11-03 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
US8601579B2 (en) * 2011-06-03 2013-12-03 Apple Inc. System and method for preserving references in sandboxes
PT2717917T (pt) 2011-07-05 2016-07-27 Bioasis Technologies Inc Conjugados de anticorpos p97
CA2848417C (en) * 2011-09-21 2023-05-02 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
US8895264B2 (en) 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
WO2013130807A1 (en) * 2012-02-28 2013-09-06 Sigma-Aldrich Co. Llc Targeted histone acetylation
EP2847338B1 (en) * 2012-05-07 2018-09-19 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
ES2613691T3 (es) 2012-07-11 2017-05-25 Sangamo Biosciences, Inc. Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal
EP2911687B1 (en) 2012-10-26 2019-02-13 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
US9873894B2 (en) 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US20160237455A1 (en) 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
ES2813367T3 (es) * 2013-12-09 2021-03-23 Sangamo Therapeutics Inc Métodos y composiciones para ingeniería genómica
US9841814B1 (en) * 2017-01-27 2017-12-12 Emergent AR Platforms Corp. Intentional user experience

Also Published As

Publication number Publication date
AU2014363991A1 (en) 2016-06-09
IL245785B (en) 2021-06-30
CN105874071A (zh) 2016-08-17
US20150159172A1 (en) 2015-06-11
WO2015089046A1 (en) 2015-06-18
EP3080143A4 (en) 2017-06-14
JP6535684B2 (ja) 2019-06-26
IL277196B (en) 2022-03-01
US10081661B2 (en) 2018-09-25
CN111330021A (zh) 2020-06-26
EP3080274A2 (en) 2016-10-19
AU2020277091B2 (en) 2023-05-11
JP6642943B2 (ja) 2020-02-12
US20180362601A1 (en) 2018-12-20
IL245778A0 (en) 2016-07-31
JP2017500061A (ja) 2017-01-05
CN105940013B (zh) 2020-03-27
US20190345208A1 (en) 2019-11-14
EP3080274A4 (en) 2017-06-21
IL277196A (en) 2020-10-29
US20210188926A1 (en) 2021-06-24
AU2014364051B2 (en) 2018-12-20
IL245778B (en) 2021-06-30
US10407476B2 (en) 2019-09-10
EP3757116A1 (en) 2020-12-30
US11634463B2 (en) 2023-04-25
HK1225754A1 (zh) 2017-09-15
JP2017504354A (ja) 2017-02-09
CA2931848A1 (en) 2015-06-18
CN105874071B (zh) 2020-04-14
WO2015089077A3 (en) 2015-09-03
ES2813367T3 (es) 2021-03-23
JP2019037254A (ja) 2019-03-14
AU2020277091A1 (en) 2020-12-24
IL245785A0 (en) 2016-07-31
HUE051628T2 (hu) 2021-03-01
AU2014364051A1 (en) 2016-06-09
AU2014363991B2 (en) 2020-08-27
US10968261B2 (en) 2021-04-06
US9771403B2 (en) 2017-09-26
WO2015089077A2 (en) 2015-06-18
US20170342118A1 (en) 2017-11-30
EP3080274B1 (en) 2020-06-03
CA2931637A1 (en) 2015-06-18
AU2020277091C1 (en) 2023-11-02
EP3080143A1 (en) 2016-10-19
US20150166618A1 (en) 2015-06-18
CN105940013A (zh) 2016-09-14
EP3080143B1 (en) 2019-02-20
CA3229275A1 (en) 2015-06-18
CA2931637C (en) 2023-10-10

Similar Documents

Publication Publication Date Title
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
DK3441468T3 (da) Afgivelsesfremgangsmåder og sammensætninger til nukleasemedieret genom-manipulation
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3108009T3 (da) Fremgangsmåder og sammensætninger til DNA-profilering
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK3125927T3 (da) Fremgangsmåder og sammensætninger til immunmodulering
DK3169741T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK2981822T3 (da) Sammensætninger og fremgangsmåder til vækstfaktormodulation
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3060200T3 (da) Tyrosinderivater og sammensætninger dermed
DK3077346T3 (da) Bindemiddelsammensætning til forbedrede mørtler og belægninger
DK3024428T3 (da) Sammensætninger og fremgangsmåder til dental mineralisering
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf